Beta Ig-h3/TGFBI Antibody [Alexa Fluor™ Plus 680]

• Reactivity: Mu
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Alexa Fluor Plus 680

Beta Ig-h3/TGFBI Antibody [Alexa Fluor™ Plus 680] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse beta IG-H3
• Specificity: Detects mouse beta IG-H3 in ELISAs and Western blots. In sandwich immunoassays, less than 6% cross-reactivity with recombinant human (rh) beta IG-H3 is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Beta Ig-h3/TGFBI Antibody [Alexa Fluor™ Plus 680]

• beta IGH3
• beta IG-H3
• BIGH3EBMD
• CDB1
• CDG2
• CDGG1transforming growth factor, beta-induced, 68kD
• CSD
• CSD1
• CSD2
• CSD3
• Kerato-epithelin
• LCD1
• RGD-CAP
• RGD-containing collagen-associated protein
• TGFBI
• TGFBIP
• transforming growth factor, beta-induced, 68kDa
• transforming growth factor-beta-induced protein ig-h3

Background

Beta IG-H3, also known as TGFBI and RGD-CAP, is a matricellular adaptor protein that is induced in most cell types in response to TGF-beta stimulation (1‑4). The mouse beta IG-H3 cDNA encodes a 683 amino acid (aa) precursor that includes a 23 aa signal sequence, one EMI domain, four FAS1 domains, and one RGD motif (2). Mouse beta IG-H3 shares 91% aa sequence identity with human and porcine beta IG-H3. beta IG-H3 is expressed as a 75 kDa protein with no post-translational additions (5). Following secretion, cleavages at multiple positions near the C-terminal end liberate peptides with pro-apoptotic activity (5, 6). Peptides that encompass the RGD motif contribute to the pro-apoptotic effects of TGF-beta (6). FAS1 domains contain YH motifs that are characterized by conserved Tyr and His residues (7). The YH motifs in each of the FAS1 domains enable beta IG-H3 to bind to matrix fibronectin, collagen I, collagen VI, biglycan, and decorin (3, 8‑11), in addition to cell expressed integrins alpha V/ beta 3, alpha V beta 5, and alpha 3 beta 1 (7, 8, 12, 13). The expression of beta IG-H3 is modulated at particular developmental stages in some cell types. It is upregulated in keratinocytes and immature dendritic cells but downregulated in osteoblasts (8, 12, 14). It promotes keratinocyte differentiation but blocks osteoblast differentiation (8, 12). beta IG-H3 stimulates macrophage endocytosis and vascular endothelial cell proliferation and migration (13, 14). High glucose levels induce beta IG-H3 in renal proximal tubule cells which is predictive of diabetic nephropathy (3). Several point mutations (clustered in the fourth FAS1 domain) of beta IG-H3 are linked to different corneal dystrophies (15). beta IG-H3 is downregulated in many cancers (4, 16) and functions as a suppressor of tumorigenicity when overexpressed (2, 4, 16).

1. Skonier, J. et al. (1992) DNA Cell Biol. 11:511.
2. Skonier, J. et al. (1994) DNA Cell Biol. 13:571.
3. Lee, S-H. et al. (2003) Kidney Int. 64:1012.
4. Zhao, Y.L. et al. (2002) Oncogene 21:7471.
5. Andersen, R.B. et al. (2004) Biochemistry 43:16374.
6. Kim, J-E. et al. (2003) Oncogene 22:2045.
7. Kim, J-E. et al. (2002) J. Biol. Chem. 277:46159.
8. Thapa, N. et al. (2005) Bone 36:232.
9. Hanssen, E. et al. (2003) J. Biol. Chem. 278:24334.
10. Billings, P.C. et al. (2002) J. Biol. Chem. 277:28003.
11. Reinboth, B. et al. (2006) J. Biol. Chem. 281:7816.
12. Oh, J-E. et al. (2005) J. Biol. Chem. 280:21629.
13. Nam, J-O. et al. (2003) J. Biol. Chem. 278:25902.
14. Cao, W. et al. (2006) Blood 107:2777.
15. Stewart, H.S. et al. (1999) Hum. Mutat. 14:126.
16. Zhao, Y. et al. (2006) Mol. Carcinog. 45:84.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.